F-1: Tianan Technology Group Ltd. F-1 Registration Statement

Tianan Technology Group Ltd. is registering 10,000,000 ordinary shares for resale by existing shareholders.

Summary

• Tianan Technology Group Ltd. is a BVI holding company conducting operations through its Chinese subsidiaries, Shanghai Qige and Henan Qige.
• The company specializes in graphene-based health therapy products, including saunas, heating blankets, pillows, and knee pads.
• This filing registers 10,000,000 ordinary shares for resale by existing shareholders; the company will receive no proceeds from these sales.
• The company reported revenue of $1,783,130 for the fiscal year ended December 31, 2024, and $471,198 for the six months ended June 30, 2025.
• Net income was $454,590 for fiscal year 2024 and $20,115 for the six months ended June 30, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a high-risk registration statement due to the company's reliance on Chinese operations, material weaknesses in internal controls, and the speculative nature of the graphene health therapy market.

Positives

• Significant revenue growth of 623% in fiscal year 2024 compared to 2023.
• Transitioned from an operating loss in 2023 to net income in 2024 and the first half of 2025.
• Established a diversified product line in the growing graphene health therapy market.
• Implemented a dual-track settlement mechanism to balance cash flow and customer loyalty.

Negatives

• The company has no material operations of its own, relying entirely on Chinese subsidiaries.
• Identified material weaknesses in internal control over financial reporting, including a lack of accounting staff with U.S. GAAP expertise.
• The company does not currently hold product liability insurance.
• Significant concentration of revenue in a limited number of customers.

Risks

• Substantial regulatory and political risks associated with operating in China, including potential government intervention.
• Uncertainty regarding the ability to remit dividends or capital out of China due to foreign exchange controls.
• Risk of delisting or trading prohibitions under the Holding Foreign Companies Accountable Act (HFCA Act) if audit inspections are restricted.
• Dependence on key personnel, specifically founder and CEO Mr. Heng Fei Yang.
• The company is a 'penny stock' and there is no guarantee an active trading market will develop.

Future Outlook

The company expects the Chinese health industry to sustain a compound annual growth rate of around 10% and plans to expand its sales network, invest in R&D, and potentially pursue horizontal or vertical acquisitions.

Management Comments

• Management believes the company is well-positioned to capitalize on the growing graphene industry within the health therapy sector.
• Management intends to continue to adhere to business principles of providing high-quality and safe products to consumers.

Industry Context

StockSavvy.ai notes that the company operates in the highly competitive and rapidly evolving graphene-based health therapy market in China, which is subject to significant regulatory oversight and policy shifts.

Comparison to Industry Standards

• Competitors include Anhui Aerospace Pim Health Technology Co., Ltd. and Zhejiang Zhongjun Graphene Technology Co., Ltd.
• The company faces competition from firms with potentially greater capital resources, broader product portfolios, and more established brand recognition.

Corporate Governance

Related Party Transactions

• Loans from CEO Mr. Heng Fei Yang.
• Sales agreements with Suzhou Aixi Health Technology Co., Ltd. and Shanghai Shengji Trade Co., Ltd., both under common control or management.

Stakeholder Impact

• Shareholders face risks related to the company's corporate structure and potential regulatory actions in China.
• Employees may be impacted by the company's efforts to implement a market-oriented compensation structure.

Next Steps

• Seek quotation of ordinary shares on the OTCQX or OTCQB Venture.
• Continue to implement remedial measures for identified material weaknesses in internal control.
• Expand sales and distribution network into new geographic markets.

Key Dates

Recommendation

The stock is highly speculative given the regulatory risks of Chinese operations and the lack of an established public market, warranting a cautious 'hold' until more operational stability and governance improvements are demonstrated.

Keywords

graphene, health therapy, far-infrared, China, holding company, resale, F-1